Summit Therapeutics Inc.

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-26 EDT			5-day change	1st Jan Change
7.77 ^USD	-3.00%		-2.14%	+197.70%

06-24	Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer	CI
06-24	Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer	CI

Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP

June 17, 2024

On June 18, 2024, Summit Therapeutics Inc. closed the transaction. The transaction included participation from 2 investors.

Latest news about Summit Therapeutics Inc.

Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer	06-24	CI
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer	06-24	CI
Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP	06-17	CI
Summit Therapeutics Inc. Announces Resignation of Ujwala Mahatme as Member of its Board	06-13	CI
Sector Update: Health Care Stocks Steady Premarket Monday	06-03	MT
Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating	06-03	MT
Transcript : Summit Therapeutics Inc. - Special Call	06-03
Summit Therapeutics Generates $200 Million Through Share Sale; Expand License Territories for Ivonescimab	06-03	MT
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	06-03	CI
Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP	06-02	CI
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	05-31	MT
Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations	05-31	MT
Sector Update: Health Care	05-31	MT
US Futures Trend Modestly Lower Pre-Bell Friday as Investors Await Key Inflation Report	05-31	MT
Health Care Stocks Steady -- Health Care Roundup	05-30	DJ
Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival	05-30	CI
US Equities Markets Close Lower Thursday After Q1 Economic Growth Found to be Slower Than Projected	05-30	MT
Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar	05-30	MT
Summit Therapeutics Shares Triple After Drug Candidate Data	05-30	DJ
Summit Therapeutics cancer therapy succeeds in late-stage China study	05-30	RE
Summit Therapeutics Stock Trading Halted, Pending Material News Release	05-30	MT
Sector Update: Health Care Stocks Decline Late Friday Afternoon	05-24	MT
Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced	05-24	MT
Top Premarket Decliners	05-24	MT
Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target	05-07	MT

Chart Summit Therapeutics Inc.

Duration

Period

More charts

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.155 GBP

Average target price

10.58 GBP

Spread / Average Target

+71.90%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SUMMIT THERAPEUTICS INC.	+197.70%	5.45B
VERTEX PHARMACEUTICALS INCORPORATED	+16.49%	122B
REGENERON PHARMACEUTICALS, INC.	+21.73%	115B
ARGENX SE	+22.24%	26.64B
BIONTECH SE	-21.81%	19.91B
GENMAB A/S	-16.87%	16.32B
BEIGENE, LTD.	-18.81%	15.49B
WUXI APPTEC CO., LTD.	-44.74%	15.52B
SAREPTA THERAPEUTICS, INC.	+62.72%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+3.09%	13.67B

Bio Therapeutic Drugs